Search results for: infliximab

First Biosimilar Drugs Approved in U.S., Canada

Michele B. Kaufman, PharmD, BCGP | May 15, 2015

The first biosmilar products have been approved in the U.S. and Canada, following Europe’s early lead. Canada approved its first biosimilar monoclonal antibody (mAb) therapy, known as Inflectra (infliximab), on March 30, 2015.1 In Canada, biosimilars are being called subsequent entry biologic (SEB) agents. Inflectra is approved for treating patients with rheumatoid arthritis (RA), ankylosing…

Imaging in Ankylosing Spondylitis

Susanne Juhl Pedersen, MD, PhD | April 1, 2015

MRI inflammation, fat and new bone formation in the sacroiliac joints, spine in patients with AS

Medication Non-Adherence by Rheumatology Patients & What Rheumatologists Can Do

Jennifer Stichman, MD, and Dennis J. Boyle, MD | April 1, 2015

Lack of efficacy, poor DAS scores may be misinterpreted as a drug failure

Coding Corner Question: March

From the College | March 2, 2015

Coding for chemotherapy infusion with a drug reaction

2014 ACR/ARHP Annual Meeting: Diagnosis, Management of Sarcoidosis in the Heart, Central Nervous System

Kathy Holliman | March 1, 2015

Without reliable diagnostic tests or evidence-based treatment guidelines, patient symptoms critical to diagnosing disease

Case Report: Rheumatoid Arthritis and Degenerative Disk Disease

Patricia Frisch, PhD; Ronald R. Butendieck, MD; Andy Abril, MD; Peter M. McIntosh, MD; Salim M. Ghazi, MD; Elliot L. Dimberg, MD; Lynn F. Feldman, DO; David G. Lucas, MD; and Andrea Styron, MSR-PT | March 1, 2015

Combination therapy includes abatacept for patient with erosive, chronic RA, underlying osteoarthritis and degenerative disk disease

Coding Corner Answer: March

Staff | March 1, 2015

Coding for chemotherapy infusion with a drug reaction

The ACR Advocates for Drug Coverage, Payment Policies to Protect Rheumatology Patients, Practices

E. William St.Clair, MD | February 1, 2015

Rheumatologists must be adequately compensated for managing patients with complex drug therapies and Medicare beneficiaries need access to biologic treatments

2014 ACR/ARHP Annual Meeting: Rheumatology Drug Updates, Safety News

Michele B. Kaufman, PharmD, BCGP | January 1, 2015

Plus, hydrocodone combination products and brodalumab

The ACR/ARHP Annual Meeting: Rheumatoid Arthritis Raises Mortality Risk in Women

Kathy Holliman | January 1, 2015

Data from Nurses’ Health Study, other clinical trials point to higher risk of respiratory, cardiovascular disease death in women with RA